Frequently asked questions (FAQs) No, GLP-1 is not the same as Ozempic, but Ozempic is a type of GLP-1 medication
The arrival of oral GLP-1 therapies marks the beginning of a new chapter in obesity pharmacotherapy
Optimize Your Peptide Therapy Journey Take control of your peptide therapy with PeptideKit - the comprehensive app designed to help you track, monitor, and optimize your treatment: Add peptide therapy protocols with custom schedules that work for you Easy dose logging with customizable reminder notifications Body change tracking to monitor your transformation Progress visualization with charts and trend analysis The Bottom Line Reconstituting peptides might feel daunting the first time, but it's a straightforward process once you understand the basics
Semaglutide 2.4 mg (Wegovy): ~15% body weight loss at 68 weeks in clinical trials Tirzepatide 15 mg (Zepbound): ~21% body weight loss at 72 weeks in clinical trials Real-world data shows lower results: Cleveland Clinic research from 2025 found average weight loss of 7.7% with semaglutide and 12.4% with tirzepatide at one year in routine clinical practice
Prediction of the effects of liraglutide on kidney and cardiovascular outcomes based on short-term changes in multiple risk markers
The NICE Guideline NG239 (2024) and the AAFP clinical review both support this approach